Livagen

Livagen is described as being related to the peptide Epithalon and is discussed for helping regulate the immune system, the GI tract, and the liver.

This peptide is described as acting as a bio-regulator that interacts directly with DNA and influences gene expression. In research discussions, its anti-aging support is often described as helping “wake up” silenced genes to promote better overall health.

Deeper Research Notes (Mechanism Summary):
• Described as influencing DNA structure in lymphocytes by “unpacking” chromatin to activate silenced genes—enhancing lymphocyte activity and supporting antibodies and cytokines involved in immune response.
• Discussed for supporting heart health by modulating lymphocyte gene activity, potentially reducing inflammation and scarring, which may help lower heart-disease risk.
• For the GI tract, discussed for boosting enkephalins (natural pain-relief peptides) that help maintain gut-lining integrity and reduce damage from inflammation and infections.

Caution & Contraindications:
Caution:
• May cause headache, nausea, and stomach discomfort
• Use caution in individuals with a history of active autoimmune conditions and/or individuals undergoing immunosuppressive therapy
Contraindications:
• Generally well tolerated based on current research

Reconstitution Options (Vial Format):
• 20 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Add bacteriostatic water slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Choose a diluent volume that makes a 1–5 mg dose easy to measure accurately.
• Store according to the product label/spec sheet and protect from light as applicable.

Sequence: Lys-Glu-Asp-Ala

Molecular Formula: C₁₈H₃₁N₅O₉

Molecular Weight: 461.5 g mol^-1

PubChem CID: 87919683

CAS Number: 195875-84-4

DNA resides within the nucleus of eukaryotic organisms, such as humans, and undergoes a hierarchical organization to fit the approximately 3 feet of DNA within a human cell into a space just one-hundredth of a millimeter in size. This packaging process effectively reduces the DNA's size by about 100,000 times. The DNA double helix wraps around proteins known as histones, which assemble into chromatin structures. These chromatin structures further condense to form chromosomes. This hierarchical organization serves various purposes, including facilitating DNA replication and cell division, accommodating DNA within cells, and regulating gene expression at a high level. In essence, DNA organization primarily involves packaging genetic material and controlling access to specific genes.

One significant function of chromatin is controlling gene expression. Research conducted on older adults suggests that Livagen can activate specific genes in the lymphocytes of older individuals by decondensing chromatin. This activation includes genes, such as ribosomal genes, which indirectly contribute to enhanced protein production and increased cell activity. This information implies that Livagen has a direct impact on the DNA within lymphocytes, primary immune system cells. Studies examining the effects of Livagen, Epitalon, and Vilon administration in elderly individuals reveal four different effects of Livagen on lymphocytes: Activation of synthetic processes by reactivating ribosomal genes. Decondensation of chromatin. Alteration of gene expression. Induction of decondensation. All these effects collectively lead to the reactivation of silenced chromatin, potentially rejuvenating lymphocytes to a more youthful state.

Lymphocytes also play a crucial role in cardiac health. Research suggests that dysregulation of chromatin structure in lymphocytes is a contributing factor to conditions like hypertrophic cardiomyopathy (HCM) and atherosclerosis. Livagen's ability to decondense chromatin aligns with this problem and has prompted extensive research. By influencing lymphocyte gene expression, Livagen may reduce inflammation and scarring associated with heart disease. It might also be useful in preventing HCM in genetically predisposed individuals and aiding recovery after a heart attack or other cardiac injuries, potentially lowering morbidity and mortality related to heart disease.

Livagen impacts pain management by inhibiting enkephalin-degrading enzymes in the blood, thereby increasing natural painkiller levels in the body. Ongoing research is investigating its effectiveness in pain control, potential side effects related to enhanced enkephalin levels, and any addictive potential.

Recent research indicates that Livagen affects the mucosal barrier of the gastrointestinal (GI) tract. Activation of mu and delta receptors by Livagen increases vagal nerve signaling to the GI tract and alters mucosal nitric oxide and prostaglandin levels. This leads to significant gastroprotection, potentially beneficial in treating infectious diarrhea and mitigating symptoms and long-term effects of inflammatory bowel disease. Livagen's ability to enhance receptor activation by increasing enkephalin levels suggests its potential use in various GI tract disorders.

Research has revealed that many aging-related effects stem from changes in DNA organization, specifically chromatin condensation. This condensation silences genes and impairs repair processes, accelerating aging. Reversing this process by decondensing DNA may extend lifespan. Studies by Professor Teimuraz Lezhava suggest that Livagen, Epitalon, and other bioregulatory peptides impact this process by decondensing DNA. This research provides hope that these peptides can counteract age-related dysfunctions, particularly in immune regulation and protein synthesis.

In summary, Livagen is a bioregulatory peptide with direct effects on DNA structure and function. It is renowned for its ability to decondense chromatin, leading to increased gene expression and rejuvenation of cells. Livagen's most extensively studied effects are on immune system lymphocytes, offering potential benefits in heart health, pain management, GI tract disorders, and aging-related dysfunctions. Research continues to uncover Livagen's promise, shedding light on the processes of aging and senescence. Please note that Livagen is primarily intended for educational and scientific research, and it is not meant for human consumption without proper licensing.

PubMed

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.